In a Phase 1 clinical trial, Metsera’s MET-097 exhibited promising weight loss outcomes, supporting its potential for once-monthly dosing. The 125 participants in the trial received various doses of MET-097.
Key Findings:
• MET-097 demonstrated significant and sustained weight loss, achieving a 7.5% reduction in body weight.
• The weight loss was maintained for at least 4 weeks after the last dose, indicating extended efficacy.
• MET-097’s long half-life of 380 hours enables potential monthly or less frequent dosing, eliminating the need for titration.
Benefits and Impact:
• Once-monthly dosing simplifies administration and improves patient adherence.
• The extended efficacy reduces the burden of frequent injections.
• Metsera’s HALO™ platform technology underlies MET-097, providing a unique advantage in achieving ultra-long-acting GLP-1 therapies.
Next Steps:
• Metsera plans to initiate a Phase 2b trial in Q4 2024, with data expected in the first half of 2025.
• The company is developing a portfolio of oral and injectable therapies targeting multiple therapeutic areas within obesity and metabolic diseases.
Metsera’s advancements in GLP-1 agonists aim to provide more convenient, effective, and scalable weight loss treatments, addressing the evolving needs of the obesity treatment landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
